Leslie Massey
Australia's COVID-19 vaccine rollout has been slower than that of other countries, including the UK and the US. As of June 2021, only around 3% of the population was fully vaccinated, and the government had to scrap its target of vaccinating all Australians by October 2021. The rollout has been affected by supply issues, medical advice discouraging the use of the AstraZeneca vaccine for those under 50, and vaccine hesitancy. Australia's handling of the pandemic has been praised, with low infection rates and deaths compared to other nations. However, the slow vaccine rollout has been a concern, with the country lagging behind in vaccination rates per 100 people when compared to other OECD countries.
| Characteristics | Values |
|---|---|
| Vaccines approved for administration in Australia | Pfizer-BioNTech, AstraZeneca, Moderna |
| Number of doses administered by 28 April 2021 | 2 million |
| Number of doses administered by February 2021 | 6.1 million |
| Percentage of population fully vaccinated by February 2021 | 3% |
| Number of doses delivered per 100 people | 23 |
| Number of doses delivered per 100 people in the UK | 106.1 |
| Number of doses delivered per 100 people in the US | 92.9 |
| Number of doses delivered per 100 people in Germany | 73.3 |
| Percentage of people living in disability residential accommodation fully vaccinated by June 2021 | <2% |
Explore related products
$11.93 $21.99
What You'll Learn
Vaccine hesitancy and supply issues
Australia's success in battling Covid-19 has been overshadowed by its sluggish vaccination efforts. The country has been slower than most others to immunise its population, with some high-risk groups crying out for protection. While progress has recently accelerated, supply shortages and mismanagement have been blamed for the delays.
Vaccine hesitancy
Vaccine hesitancy in some pockets of the community has also risen, even as the pace of the rollout has picked up. A survey found that about one-third of Australians said they were unlikely to get vaccinated. The caution centred around side effects and a lack of urgency given Australia's low infection rates. Other factors driving vaccine hesitancy include a lack of trust in the health system or government and exposure to misinformation and conspiracy theories, particularly among cultural groups with historical mistrust of authorities.
Supply issues
Supplies have also been an issue, with doctors administering vaccines at clinics speaking out about shortages. The rollout has been further impacted by a tussle with the European Union, which led to part of the AstraZeneca order being held back, and domestic production not living up to expectations. The government's advice that people under 60 get a Pfizer vaccine is expected to put a strain on stockpiles. Australia is due to receive 40 million doses of the Pfizer jab in 2021, but it's unclear how many doses are currently available.
Australian Coffee: Brewing the Perfect Cup
You may want to see also
Explore related products
AstraZeneca setbacks
Australia's vaccination programme began in February 2021, with the AstraZeneca vaccine originally slated as the cornerstone of the entire programme. However, the rollout faced several setbacks, including concerns about the safety of the AstraZeneca vaccine, which contributed to vaccine hesitancy and slowed down the immunisation programme.
One of the earliest reported serious adverse events was a 44-year-old man admitted to Melbourne's Box Hill Hospital on 2 April 2021, after developing serious thrombosis and thrombocytopenia syndrome (TTS) after receiving the AstraZeneca vaccine. Similar cases had been reported overseas, and this event prompted the TGA to issue a warning. In April, a 48-year-old woman died in John Hunter Hospital after developing TTS four days after receiving the AstraZeneca vaccine. This was the first death in Australia likely linked to a COVID-19 vaccination. Since then, further cases of serious adverse events and two additional deaths following COVID-19 vaccination have been reported.
In April 2021, the Australian Technical Advisory Group on Immunisation (Atagi) advised that due to "rare but serious" blood clots, the AstraZeneca vaccine should not be the preferred vaccine for people under 50. This announcement was met with widespread confusion and rocked public confidence in the vaccine. The government's decision to recommend Pfizer for under-50s put a strain on Pfizer stockpiles, as Australia only had a limited supply at the time.
The AstraZeneca vaccine was the main component of Australia's immunisation programme, and the setback with the vaccine contributed to a sluggish vaccination effort. The government faced supply pressure and criticism for its handling of the pandemic, including its decision-making and access to crucial data. As a result, Australia's vaccination rate lagged behind other countries, including the UK and the US.
To address the setbacks, steps were taken to speed up the rollout, such as mass immunisation hubs. However, the government struggled to provide clear numbers on vaccination rates, particularly among aged care workers. Experts emphasised the need for better public health messaging and an easy-to-understand national advertising campaign to improve vaccine uptake and address vaccine hesitancy.
Square Poop Mystery: Which Australian Animal Does This?
You may want to see also
Explore related products
Rollout progress
Australia's COVID-19 vaccine rollout began in February 2021, with 142,000 doses of the Pfizer-BioNTech vaccine arriving in the country. The rollout has faced several setbacks, including supply issues, vaccine hesitancy, and medical advice discouraging the use of the AstraZeneca vaccine for those under 50 due to rare cases of blood clotting.
By June 2021, around 3% of the population was fully vaccinated, and the government had to abandon its target of vaccinating all Australians by October 2021. Steps were taken to speed up the rollout, such as mass immunisation hubs, and by April 2021, over 2 million vaccinations had been administered. However, this was still 3 million short of the original plan.
The vaccine rollout has not been uniform across Australia, with state and federal governments dividing the task. As of June 2021, fewer than 2% of people in disability residential accommodation had been fully vaccinated, and the government could not provide clear numbers on vaccinated aged care workers.
Australia's vaccination rate has lagged behind other countries, delivering 23 doses per 100 people compared to 106.1 doses per 100 people in the UK and 92.9 in the US. By July 2021, Australia entered the "Vaccination Consolidation Phase", with the federal government and all states agreeing on a revised four-phase plan to transition the country's COVID-19 response.
Soccer Ball Size for U12s in Australia
You may want to see also
Explore related products
International comparisons
Australia's COVID-19 vaccination rollout began in February 2021, with 142,000 doses of the Pfizer-BioNTech vaccine and 300,000 doses of the Oxford-AstraZeneca vaccine. The country's vaccination campaign initially faced criticism for its slow pace and late start, falling far below the initial government targets. However, Australia began vaccinating its citizens at a comparatively fast pace, overtaking the United States in first-dose coverage by 10 October 2021.
By 28 April 2021, more than two million COVID-19 vaccinations had been administered, and by 16 August 2021, more than 10 million Australians had received their first dose. As of 3 August 2022, Australia had administered 62,492,656 vaccine doses across the country, with over 95% of the population aged 12 and over fully vaccinated.
Australia's vaccination rate can be compared to other countries to provide a global perspective. According to Our World Data, as of November 2022, about 80% of people in high-income countries had received at least one vaccine dose, while only 23% of those in low-income countries had received their first dose. High-income countries had already given a first dose to a majority of their populations by early July 2021, while low-income countries barely passed 1% during the same period.
In terms of specific countries, Australia's vaccination rate has been compared to that of the United Kingdom, the United States, and Germany. By June 2021, Australia had delivered 23 doses per 100 people, while the UK had administered 106.1 doses, the US 92.9, and Germany 73.3. Australia was considered one of the worst performers in the Organisation for Economic Co-operation and Development (OECD), with only Japan and New Zealand having lower vaccination rates per 100 people.
Despite the early setbacks, Australia's vaccination campaign accelerated, and it eventually overtook the United States in first-dose coverage. This demonstrates the country's ability to adapt and improve its vaccination drive, ultimately achieving a high vaccination rate comparable to other developed nations.
Hoofed Animals in Australia: Are They Native?
You may want to see also
Explore related products
Adverse events
Australia's vaccination rollout has faced challenges due to concerns about the safety of the AstraZeneca vaccine, which was initially the main component of the country's immunisation program. Medical advice discouraging its use in people under 50 due to the risk of vaccine-related blood clotting resulted in a setback for the program. This concern was highlighted by a 44-year-old man who developed thrombosis and thrombocytopenia syndrome (TTS) after receiving the AstraZeneca vaccine. Similar cases had been reported internationally. Unfortunately, a 48-year-old woman with underlying health conditions died in Australia, likely due to TTS following her AstraZeneca vaccination. These incidents prompted the Therapeutic Goods Administration (TGA) to advise individuals experiencing persistent headaches or other concerning symptoms within 4 to 20 days of vaccination to seek medical advice.
The TGA plays a crucial role in monitoring adverse events following immunisation (AEFI) through national passive surveillance. The reporting is voluntary, and anyone, including consumers, parents, health professionals, immunisation providers, and pharmaceutical companies, can report adverse events to the TGA's Office of Product Review or their state or territory health service. The TGA reviews all reports and sends vaccine-related AEFI reports to the National Centre for Immunisation Research and Surveillance (NCIRS) for analysis and publication in national AEFI surveillance reports. NCIRS also leads the AusVaxSafety initiative, which actively monitors vaccine safety through various surveillance systems, such as AEFI-CAN and MedicineInsight Data.
To ensure the safety of vaccines, Australia requires all vaccines to undergo stringent clinical trials and safety evaluations before approval by the TGA. Post-licensure safety surveillance is also conducted through the detection and notification of adverse events. An AEFI refers to any unfavourable medical occurrence following immunisation, which may or may not be causally related to the vaccine. Most reactions are mild and transient, but serious adverse events, such as anaphylaxis, can be life-threatening and require immediate treatment.
The management of adverse events includes observing patients for at least 15 minutes post-vaccination, as most life-threatening events occur within 10 minutes. Patients experiencing adverse events should be managed according to the Australian Immunisation Handbook, and health professionals should be trained to recognise and manage anaphylaxis. Additionally, consumers can report vaccine side effects by calling the Adverse Events Medicine Line, which is answered by registered pharmacists.
Australian Shepherds: Natural Swimmers or Not?
You may want to see also
Frequently asked questions
As of 2021, around 3% of the population has been fully vaccinated.
The government has implemented mass immunisation hubs to speed up the rollout.
Australia has delivered 23 doses per 100 people, which is lower than other OECD countries.
The four vaccines currently approved for administration in Australia are Pfizer-BioNTech, AstraZeneca, Moderna, and Novavax.
In 2021, there were no special privileges for vaccinated people in Australia, unlike some other countries.
